Revolution Medicines, Inc. (RVMD) shareholders
Close on Nov 17, 2026Market cap $34.87BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (7.20%) | 15,402,103 | 7.20% | 13G (passive) amendment | Sep 30, 2026 |
| Luo Patrick (Cheng) Joint filing with Wehrly, Mark C. (7.50%), Dreyfuss, Philip D. (7.50%) and 13 more | 14,596,149 | 7.50% | 13G (passive) amendment | Dec 31, 2025 |
| Kim, David T. Joint filing with Dapice Joshua J. (6.40%), Dreyfuss, Philip D. (6.40%) and 13 more | 13,564,149 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Fried, Richard B Joint filing with Wehrly, Mark C. (7.90%), Dreyfuss, Philip D. (7.90%) and 15 more | 13,262,045 | 7.90% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 12,201,395 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Baker Bros. Advisors (GP) LLC Joint filing with Baker Bros. Advisors LP (5.30%), Felix J. Baker (5.30%) and 1 more | 11,443,357 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Saito Edric C. Joint filing with Wehrly, Mark C. (6.80%), Dreyfuss, Philip D. (6.80%) and 14 more | 11,331,045 | 6.80% | 13G (passive) amendment | Sep 30, 2024 |
| Vanguard Capital Management | 10,999,044 | 5.13% | 13G (passive) | Sep 30, 2026 |
| JANUS HENDERSON GROUP Ltd. | 10,736,145 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (5.50%), Wellington Investment Advisors Holdings LLP (5.50%) and 1 more | 10,259,738 | 5.50% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RVMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,695,790 | – | $2.56B | +2,483,084 | 0.04% |
| Farallon Capital Management LLC | 13,550,796 | – | $2.54B | −54,000 | 11.71% |
| FMR LLC | 12,200,422 | – | $2.28B | +3,736,108 | 0.10% |
| Baker Bros. Advisors LP | 11,443,357 | – | $2.14B | +1,888,000 | 10.74% |
| Jupiter Topco LLC | 10,736,145 | – | $2.01B | New | 0.82% |
| Darwin Global Management, Ltd. | 10,629,822 | – | $2.05B | +8,418,804 | 54.45% |
| Vanguard Capital Management LLC | 9,088,661 | – | $1.70B | +726,377 | 0.04% |
| Vanguard Portfolio Management LLC | 8,294,855 | – | $1.55B | +792,232 | 0.07% |
| Nextech Invest, Ltd. | 7,601,087 | – | $1.42B | – | 67.55% |
| Paradigm Biocapital Advisors LP | 6,361,323 | – | $1.19B | −294,380 | 22.31% |
| UBS Group AG | 5,448,364 | – | $1.02B | +1,061,573 | 0.13% |
| State Street Corp | 4,897,051 | – | $917.12M | +494,389 | 0.03% |
| Capital World Investors | 4,008,244 | – | $750.66M | New | 0.09% |
| Geode Capital Management, LLC | 3,942,676 | – | $736.81M | +604,534 | 0.04% |
| Wellington Management Group Llp | 3,843,415 | – | $719.79M | −2,184,404 | 0.12% |
| JPMorgan Chase & Co | 3,298,066 | – | $636.93M | +2,996,673 | 0.04% |
| Bvf Inc/Il | 2,965,160 | – | $555.32M | +108,378 | 14.20% |
| Alphabet Inc. | 2,946,619 | – | $551.84M | −345,906 | 0.56% |
| Casdin Capital, LLC | 2,577,333 | – | $482.68M | – | 24.16% |
| Deerfield Management Company, L.P. (Series C) | 2,392,000 | – | $447.97M | +95,000 | 4.67% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 690 | 214M | 243 / 241 | 148 / 62 | 57M | 32M |
| Q1 2026 | 514 | 199M | 172 / 165 | 127 / 39 | 48M | 34M |
| Q4 2025 | 387 | 201M | 107 / 136 | 101 / 38 | 30M | 24M |
| Q3 2025 | 323 | 194M | 64 / 119 | 91 / 45 | 19M | 15M |
| Q2 2025 | 308 | 191M | 58 / 114 | 91 / 33 | 20M | 22M |
| Q1 2025 | 284 | 193M | 50 / 96 | 89 / 41 | 23M | 13M |
| Q4 2024 | 281 | 193M | 62 / 123 | 59 / 30 | 33M | 14M |
| Q3 2024 | 255 | 175M | 56 / 91 | 65 / 21 | 29M | 13M |
| Q2 2024 | 223 | 173M | 40 / 83 | 60 / 25 | 18M | 11M |
| Q1 2024 | 210 | 166M | 50 / 56 | 65 / 24 | 16M | 16M |
| Q4 2023 | 184 | 166M | 54 / 81 | 34 / 36 | 67M | 14M |
| Q3 2023 | 168 | 112M | 42 / 60 | 39 / 13 | 10M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
492 funds held RVMD in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RVMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 6,412,413 | – | $1.20B | 0.05% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 4,631,150 | – | $867.32M | 0.46% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,670,853 | – | $500.20M | 1.06% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 2,475,942 | – | $389.91M | 0.39% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 2,291,511 | – | $429.15M | 0.44% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,988,729 | – | $372.95M | 0.98% | Jul 31, 2026 |
| Growth Fund of America | 1,838,422 | – | $289.51M | 0.08% | May 31, 2026 |
| iShares Biotechnology ETF | 1,349,118 | – | $252.66M | 2.78% | Jun 30, 2026 |
| JPMorgan Large Cap Growth Fund | 1,166,558 | – | $218.47M | 0.18% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 1,128,977 | – | $211.43M | 0.98% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,011,551 | – | $159.30M | 0.37% | May 31, 2026 |
| Fidelity OTC Portfolio | 1,002,878 | – | $188.07M | 0.44% | Jul 31, 2026 |
| Janus Henderson Enterprise Fund | 978,312 | – | $183.22M | 0.82% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 942,767 | – | $148.47M | 0.65% | May 31, 2026 |
| Janus Henderson Forty Fund | 937,887 | – | $175.65M | 0.74% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Mark A. Goldsmith | See Remarks, Director | 314,766 | Sep 18, 2026 |
| Jack Anders | Chief Financial Officer | 119,216 | Nov 13, 2026 |
| Anthony Mancini | See Remarks | 39,765 | Nov 12, 2026 |
| Alan B. Sandler | Chief Development Officer | 52,559 | Oct 1, 2026 |
| Jeff Cislini | SVP & General Counsel | 51,776 | Sep 29, 2026 |
| Margaret A. Horn | Chief Operating Officer | 154,571 | Sep 18, 2026 |
| Stephen Michael Kelsey | See Remarks | 286,307 | Sep 18, 2026 |
| Xiaolin Wang | See Remarks | 116,063 | Mar 19, 2026 |
| Lin Wei | Chief Medical Officer | 101,366 | Mar 19, 2026 |
| Flavia Borellini | Director | 28,715 | Nov 17, 2026 |
| Alexis Borisy | Director | 2,329,450 | Nov 13, 2026 |
| Elizabeth M. Anderson | Director | 31,423 | Sep 24, 2026 |
| Lorence H. Kim | Director | 10,136 | Sep 10, 2026 |
| Sushil Patel | Director | 24,078 | Jul 1, 2026 |
| Sandra Horning | Director | 97,765 | Jun 23, 2026 |
| Frank Clyburn | Director | 10,929 | Jun 23, 2026 |
| Thilo Schroeder | Director | 7,601,087 | Dec 9, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Flavia Borellini Director | Nov 13, 2026 | Option exercise | +2,500 | $37.54 | $93.85K | 28,715 |
| Alexis Borisy Director | Nov 11, 2026 | Gift | −10,625 | – | – | 2,329,450 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −9,889 | $192.84 | $1.91M | 119,216 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −9,486 | $191.94 | $1.82M | 129,105 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −500 | $190.99 | $95.50K | 138,591 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −200 | $189.17 | $37.83K | 139,091 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −600 | $187.34 | $112.40K | 139,291 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −400 | $186.41 | $74.57K | 139,891 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −800 | $185.04 | $148.03K | 140,291 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −1,900 | $184.02 | $349.65K | 141,091 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −2,700 | $182.87 | $493.75K | 142,991 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −5,776 | $182.09 | $1.05M | 145,691 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Sale(10b5-1 plan) | −3,499 | $181.04 | $633.47K | 151,467 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Option exercise | +19,850 | $18.56 | $368.42K | 154,966 |
| Jack Anders Chief Financial Officer | Nov 11, 2026 | Option exercise | +15,900 | $42.45 | $674.96K | 135,116 |
| Anthony Mancini See Remarks | Nov 9, 2026 | Sale(10b5-1 plan) | −811 | $200.00 | $162.20K | 39,765 |
| Anthony Mancini See Remarks | Nov 9, 2026 | Option exercise | +1 | $102.02 | $102 | 40,576 |
| Anthony Mancini See Remarks | Nov 9, 2026 | Option exercise | +810 | $33.62 | $27.23K | 40,575 |
| Anthony Mancini See Remarks | Oct 26, 2026 | Sale(10b5-1 plan) | −2,310 | $186.99 | $431.95K | 39,765 |
| Anthony Mancini See Remarks | Oct 26, 2026 | Option exercise | +2,310 | $33.62 | $77.66K | 42,075 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −301 | $204.72 | $61.62K | 52,559 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −1,199 | $203.91 | $244.48K | 52,860 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −1,000 | $202.81 | $202.81K | 54,059 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −1,609 | $201.72 | $324.57K | 55,059 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Sale(10b5-1 plan) | −2,200 | $200.82 | $441.80K | 56,668 |
| Alan B. Sandler Chief Development Officer | Sep 29, 2026 | Option exercise | +6,000 | $58.84 | $353.04K | 58,868 |
| Jeff Cislini SVP & General Counsel | Sep 25, 2026 | Sale(10b5-1 plan) | −765 | $207.32 | $158.60K | 51,776 |
| Anthony Mancini See Remarks | Sep 25, 2026 | Option exercise | +3,121 | $33.62 | $104.93K | 42,886 |
| Anthony Mancini See Remarks | Sep 25, 2026 | Sale(10b5-1 plan) | −3,121 | $200.54 | $625.89K | 39,765 |
| Anthony Mancini See Remarks | Sep 24, 2026 | Sale(10b5-1 plan) | −587 | $200.00 | $117.40K | 39,765 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −1,500 | $194.59 | $291.89K | 4,433 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Option exercise | +5,070 | $1.12 | $5.68K | 14,476 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −910 | $191.85 | $174.58K | 13,566 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −4,985 | $192.54 | $959.81K | 8,581 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −2,648 | $193.44 | $512.23K | 5,933 |
| Elizabeth M. Anderson Director | Sep 22, 2026 | Sale(10b5-1 plan) | −100 | $195.15 | $19.52K | 4,333 |
| Anthony Mancini See Remarks | Sep 18, 2026 | Sale(10b5-1 plan) | −1,764 | $196.94 | $347.40K | 40,352 |
| Jeff Cislini SVP & General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −3,314 | $199.30 | $660.48K | 52,541 |
| Jeff Cislini SVP & General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −52 | $195.01 | $10.14K | 55,855 |
| Alan B. Sandler Chief Development Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −5 | $194.96 | $975 | 53,204 |
| Alan B. Sandler Chief Development Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −336 | $199.30 | $66.96K | 52,868 |
| Jack Anders Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −61 | $195.00 | $11.90K | 123,208 |
| Jack Anders Chief Financial Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −3,992 | $199.30 | $795.61K | 119,216 |
| Margaret A. Horn Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −76 | $195.01 | $14.82K | 154,571 |
| Margaret A. Horn Chief Operating Officer | Sep 16, 2026 | Sale(10b5-1 plan) | −4,891 | $199.30 | $974.78K | 149,680 |
| Mark A. Goldsmith See Remarks, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −13,775 | $199.30 | $2.75M | 253,342 |
| Mark A. Goldsmith See Remarks, Director | Sep 16, 2026 | Sale(10b5-1 plan) | −213 | $195.01 | $41.54K | 267,117 |
| Anthony Mancini See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −27 | $195.05 | $5.27K | 43,863 |
| Anthony Mancini See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −1,747 | $199.30 | $348.18K | 42,116 |
| Stephen Michael Kelsey See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −5,484 | $199.30 | $1.09M | 286,307 |
| Stephen Michael Kelsey See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −85 | $195.01 | $16.58K | 291,791 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Option exercise | +40,031 | $40.74 | $1.63M | 384,407 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Option exercise | +52,500 | $42.45 | $2.23M | 344,376 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −800 | $198.55 | $158.84K | 383,607 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −11,833 | $200.11 | $2.37M | 371,774 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −13,368 | $200.78 | $2.68M | 358,406 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −21,447 | $201.75 | $4.33M | 336,959 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −18,869 | $203.06 | $3.83M | 318,090 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −17,949 | $203.87 | $3.66M | 300,141 |
| Stephen Michael Kelsey See Remarks | Sep 11, 2026 | Sale(10b5-1 plan) | −4,995 | $204.84 | $1.02M | 295,146 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Revolution Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 462 shares on Sep 16, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Alan B. Sandler Officer | Sep 29, 2026 | 6,309 | $1.27M | Sep 29, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 25, 2026 | 9,363 | $1.87M | Sep 25, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 24, 2026 | 587 | $111.96K | Sep 24, 2026 | Restricted Stock Units |
| Elizabeth M. Anderson Director | Sep 22, 2026 | 15,080 | $2.91M | Sep 22, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 18, 2026 | 1,764 | $347.40K | Sep 18, 2026 | Restricted Stock Units |
| Alan B. Sandler Officer | Sep 15, 2026 | 331 | $67.45K | Sep 15, 2026 | RSU vesting |
| Anthony Mancini Officer | Sep 15, 2026 | 2,377 | $484.36K | Sep 15, 2026 | RSU vesting |
| Stephen Michael Kelsey Officer | Sep 15, 2026 | 5,415 | $1.10M | Sep 15, 2026 | RSU vesting |
| Margaret A. Horn Officer | Sep 15, 2026 | 4,830 | $984.21K | Sep 15, 2026 | RSU vesting |
| Mark A. Goldsmith Officer, Director | Sep 15, 2026 | 13,603 | $2.77M | Sep 15, 2026 | RSU vesting |
| Jeff Cislini Officer | Sep 15, 2026 | 3,272 | $666.74K | Sep 15, 2026 | RSU vesting |
| Jack Anders Officer | Sep 15, 2026 | 3,939 | $802.65K | Sep 15, 2026 | RSU vesting |
| Stephen Michael Kelsey Officer | Sep 11, 2026 | 92,531 | $18.82M | Sep 11, 2026 | Exercise of Stock Options |
| Anthony Mancini Officer | Sep 10, 2026 | 15,448 | $3.21M | Sep 10, 2026 | Exercise of Stock Options |
| Lorence H. Kim Affiliate | Aug 31, 2026 | 73,090 | $15.19M | Aug 31, 2026 | Purchase |
See a number that looks wrong?